Volume 20, Number 3—March 2014
Use of Drug-Susceptibility Testing for Management of Drug-Resistant Tuberculosis, Thailand, 2004–2008
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www.medscape.org/journal/eid; (4) view/print certificate.
Release date: February 19, 2014; Expiration date: February 19, 2015
Upon completion of this activity, participants will be able to:
• Distinguish the clinical turnaround time for drug-susceptibility testing (DST) in the current study
• Evaluate physician actions based on the results of DST in the current study
• Analyze risk factors for inappropriate treatment of tuberculosis (TB) in the current study
• Analyze risk factors for worse clinical outcomes of TB treatment in the current study.
Claudia Chesley, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Claudia Chesley has disclosed no relevant financial relationships.
Charles P. Vega, MD, Health Sciences Clinical Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.
Disclosure: Eugene Lam, MD, MSPH, MSc; Sriprapa Nateniyom, MD; Sara Whitehead, MD, MPH; Amornrat Anuwatnonthakate, MSc, PhD; Patama Monkongdee, MSc; Apiratee Kanphukiew, MSc; Jiraphun Inyapong, BNs; Wanlaya Sitti, MSc; Navarat Chiengsorn, BN; Saiyud Moolphate, MPH; Suporn Kavinum, MPH; Narin Suriyon, MPH; Pranom Limsomboon, BN; Junya Danyutapolchai, MA; Chalinthorn Sinthuwattanawibool, MSc; and Laura Jean Podewils, PhD, MS, have disclosed no relevant financial relationships.
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: February 25, 2014
- Page last updated: February 25, 2014
- Page last reviewed: February 25, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)